Print  |  Close

Clinical Trial Search Results

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.

All Clinical Trials

Records 1 - 696 of 696
1.
(Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis
Cancer Type
Leukemia
NCI ID
NCT04996875
Protocol IDs
CGT9486-20-201
2021-001010-10
NCI-2021-09477
2.
6-Hour Oxaliplatin in Preventing Nerve Damage in Patients with Advanced or Metastatic Gastrointestinal Cancer
Cancer Type
Unknown Primary
NCI ID
NCT03800693
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
3.
89Zr-TLX250 for PET/CT Imaging of ccRCC- ZIRCON Study
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT03849118
Protocol IDs
89Zr-TLX250-003
NCI-2020-02184
4.
9-ING-41 in Patients With Advanced Cancers
Cancer Type
Bladder Cancer, Bone Tumor, Brain & Spinal Cord Tumor, Breast Cancer, Lymphoma, Non-Hodgkin Lymphoma, Ovarian Cancer, Pancreatic Cancer, Sarcoma
NCI ID
NCT03678883
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
5.
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Cancer Type
Brain & Spinal Cord Tumor, Hematopoietic Malignancies, Lymphoma, Neuroblastoma
NCI ID
NCT04239092
Protocol IDs
1902
NCI-2020-04584
6.
A 5-year Longitudinal Observational Study of the Natural History and Management of Patients With HCC
Cancer Type
Liver Cancer / Hepatoblastoma
NCI ID
NCT02954094
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Atlanta
Atlanta
Piedmont Hospital - Atlanta
Atlanta
7.
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
Cancer Type
Head and Neck Cancer
NCI ID
NCT04534205
Protocol IDs
BNT113-01
NCI-2021-03177
2020-001400-41
8.
A Comparison of Three Chemotherapy Regimens for Patients with Newly Diagnosed Mantle Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04115631
Protocol IDs
Treatment Sites (2)
Emory Saint Joseph's Hospital
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
9.
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL
Cancer Type
Leukemia
NCI ID
NCT01503632
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
10.
A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT03861793
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
11.
A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT04505826
Protocol IDs
OP-1250-001
NCI-2020-13877
12.
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Cancer Type
Lung Cancer, Melanoma
NCI ID
NCT04543188
Protocol IDs
C4471001
NCI-2020-08201
13.
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT01351545
Protocol IDs
Treatment Sites (4)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Aflac Cancer and Blood Disorders Center of Children’s at Scottish Rite
Atlanta
Karen Querubin, BSN
404-785-2215
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
14.
A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma
Cancer Type
Non-Hodgkin Lymphoma
NCI ID
NCT00078598
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
15.
A Multinational, Randomized, Open-Label Study of Custirsen In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT01630733
Protocol IDs
TV1011-LC-303
2012-002447-14
16.
A Multi-site, Prospective, Observational Study in US Patients with Advanced Melanoma
Cancer Type
Melanoma
NCI ID
Protocol IDs
CA184-199
IMPULSE
BMS CA184-199
17.
A Phase 1 Study in Patients With HPV16+ Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCI ID
NCT03978689
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
18.
A Phase 1 Study of Engineered Donor Grafts (OrcaGraft/Orca-Q) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Cancer Type
Cancer-Related Syndrome, Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT03802695
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
19.
A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)
Cancer Type
Lung Cancer, Solid Tumor, Unknown Primary
NCI ID
NCT03600883
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
20.
A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies
Cancer Type
Leukemia, Lymphoma
NCI ID
NCT03420183
Protocol IDs
Treatment Sites (3)
Emory Saint Joseph's Hospital
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
21.
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
Cancer Type
Leukemia
NCI ID
NCT02723994
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
22.
A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes.
Cancer Type
Myelodysplastic Syndromes (MDS)
NCI ID
NCT01566695
Protocol IDs
Treatment Sites (1)
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
(229) 312-0406
23.
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia
Cancer Type
Leukemia
NCI ID
Protocol IDs
NCT01980875
24.
A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-agent Maintenance Versus Rituximab Maintenance in Subjects With Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma
Cancer Type
Non-Hodgkin Lymphoma
NCI ID
NCT01996865
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
25.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Kidney Cancer
NCI ID
NCT01772004
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
26.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of Avelumab (MSB0010718C) in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Head and Neck Cancer
NCI ID
NCT01772004
Protocol IDs
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
27.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Solid Tumor
NCI ID
NCT01772004
Protocol IDs
Treatment Sites (1)
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
Jamie Hodgson
706-353-2990 x279
28.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Breast Cancer
NCI ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
29.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Stomach/ Gastric Cancer
NCI ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
30.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Melanoma
NCI ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
31.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Ovarian Cancer
NCI ID
NCT01772004
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
32.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Adrenal Cancer
NCI ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
33.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Mesothelioma
NCI ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
34.
A Phase I, Open-label, Multiple-ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Subjects With Metastatic or Locally Advanced Solid Tumors and Expansion to Selected Indications
Cancer Type
Bladder Cancer
NCI ID
NCT01772004
Protocol IDs
EMR 100070-001
2013-002834-19
35.
A Phase II, Multicenter, Single-Arm Study of MPDL3280A in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Cancer Type
Bladder Cancer
NCI ID
NCT02108652
Protocol IDs
GO29293
36.
A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment
Cancer Type
Head and Neck Cancer
NCI ID
02605967
Protocol IDs
37.
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type
Melanoma
NCI ID
NCT02339571
Protocol IDs
Treatment Sites (5)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
Jamie Hodgson
706-353-2990 x279
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
38.
A Phase III Double Blind Study On The Efficacy of Topical Aloe Vera Gel on Irradiated Breast Tissue
Cancer Type
Breast Cancer
NCI ID
Protocol IDs
39.
A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
Cancer Type
Colon/Rectal Cancer
NCI ID
Protocol IDs
NCT02563002
40.
A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1-Selected Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT02486718
Protocol IDs
Treatment Sites (2)
Central Georgia Cancer Care, PC - Macon
Macon
Joanne Kerr, RN, BSN, OCN
478-743-7068
Lewis Hall Singletary Oncology Center at John D. Archbold Memorial Hospital
Thomasville
41.
A Phase III, Single-arm, Open Label, Single Study of Topical Application of a 2 Step Radiaderm Advanced Skincare System containing LactokineTM Fluid on Radiation Dermatitis in Breast Cancer Patients Treated with Adjuvant Whole Breast Radiation Therapy
Cancer Type
Breast Cancer
NCI ID
Protocol IDs
42.
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)
Cancer Type
Breast Cancer
NCI ID
NCT05104866
Protocol IDs
D9268C00001
NCI-2021-14072
43.
A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT03561220
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
44.
A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of Febrile Neutropenia
Cancer Type
Breast Cancer, Lung Cancer, Non-Hodgkin Lymphoma, Prostate Cancer
NCI ID
Protocol IDs
AMG 011 20170758
45.
A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects With Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN
Cancer Type
Breast Cancer, Lung Cancer, Non-Hodgkin Lymphoma, Prostate Cancer
NCI ID
Protocol IDs
AMG 011 20170758
46.
A Randomized Phase 2 Study of Cabozantinib (XL184) in Combination With Abiraterone in Chemotherapy Naïve Subjects With Bone-Metastatic Castration-Resistant Prostate Cancer
Cancer Type
Prostate Cancer
NCI ID
NCT01995058
Protocol IDs
XL184-210
47.
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Postmenopausal Patients With Hormone Receptor-Positive Advanced Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT02115282
Protocol IDs
E2112
NCI-2014-00746
NCI-2014-00746
ECOG-E2112
U10CA021115
U10CA180820
48.
A Randomized, Double-Blind, Phase III Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer - (KEYNOTE-355)
Cancer Type
Breast Cancer
NCI ID
NCT02819518
Protocol IDs
3475-355
NCI-2016-01555
163422
2016-001432-35
49.
A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer
Cancer Type
Breast Cancer
NCI ID
01506609
Protocol IDs
M12-895
2011-002913-12
50.
A Registry of Caris Target Now Test Results (Biomarker Expression Patterns) and Hematopoietic Diagnostics for Evaluation of Correlation with Clinical Outcomes for Cancer and other Patients
Cancer Type
Multiple Primaries
NCI ID
Protocol IDs
51.
A Registry of Caris Target Now Test Results (Biomarker Expression Patterns) for Evaluation of Correlation with Clinical Outcomes for Cancer
Cancer Type
Multiple Primaries
NCI ID
Protocol IDs
52.
A Registry of Cesium-131 Brachytherapy Plus Sub- lobar Resection for Early Stage Lung Cancer
Cancer Type
Lung Cancer
NCI ID
Protocol IDs
53.
A Robot (My Special Aflac Duck) for the Reduction of Medical Setting Distress in Pediatric Cancer Patients
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT04409301
Protocol IDs
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
54.
A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)
Cancer Type
Leukemia, Non-Hodgkin Lymphoma
NCI ID
NCT04035434
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
55.
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Cancer Type
Breast Cancer
NCI ID
NCT00781612
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
56.
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Cancer Type
Multiple Myeloma
NCI ID
NCT03374085
Protocol IDs
Treatment Sites (1)
Emory Clinic
Atlanta
57.
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
Cancer Type
Leukemia
NCI ID
NCT03336333
Protocol IDs
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Emory University Hospital - Atlanta
Atlanta
58.
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
Cancer Type
Breast Cancer
NCI ID
NCT04873362
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
59.
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Cancer Type
Breast Cancer
NCI ID
NCT04961996
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
60.
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT04546009
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
61.
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT04191499
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
62.
A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04712097
Protocol IDs
GO42909
NCI-2021-09247
2020-005239-53
63.
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT04910568
Protocol IDs
GO42552
NCI-2021-07543
2021-000238-33
64.
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors that Cannot be Removed by Surgery
Cancer Type
Unknown Primary
NCI ID
NCT04195399
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
65.
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
Cancer Type
Bone Tumor
NCI ID
NCT03706365
Protocol IDs
Treatment Sites (13)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - Canton
Canton
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
66.
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT03767244
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Atlanta
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
67.
A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
Cancer Type
Lung Cancer
NCI ID
NCT04513925
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
68.
A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)
Cancer Type
Unknown Primary
NCI ID
NCT04710576
Protocol IDs
SNDX-6352-0504
NCI-2021-01333
69.
A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT04586231
Protocol IDs
6482-011
MK-6482-011
NCI-2020-11420
2020-002075-35
70.
A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT03571568
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
71.
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
Cancer Type
Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer
NCI ID
NCT04943900
Protocol IDs
CA102-003
NCI-2021-09090
72.
A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)
Cancer Type
Hodgkin Lymphoma
NCI ID
NCT01716806
Protocol IDs
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
73.
A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT04404660
Protocol IDs
FELIX (AUTO1-AL1)
AUTO1-AL1
NCI-2020-04370
2019-001937-16
74.
A Study of Combination Chemotherapy for Patients with Newly Diagnosed DAWT and Relapsed FHWT
Cancer Type
Brain Tumor, Unknown Primary, Wilms Tumor
NCI ID
NCT04322318
Protocol IDs
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
75.
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCI ID
NCT04104776
Protocol IDs
0209-01
NCI-2020-01007
76.
A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors
Cancer Type
Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Melanoma
NCI ID
NCT05091346
Protocol IDs
E7386-G000-201
NCI-2022-02226
2021-001568-10
KEYNOTE-C83
77.
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT04607421
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
78.
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
Cancer Type
Bladder Cancer, Kidney Cancer, Unknown Primary, Ureter Cancer, Urethral Cancer
NCI ID
NCT03288545
Protocol IDs
Treatment Sites (2)
Piedmont Cancer Institute
Atlanta
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
79.
A Study of Engineered Donor Grafts (TregGraft/Orca-T) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Cancer Type
Leukemia
NCI ID
NCT04013685
Protocol IDs
TRGFT-201
NCI-2019-08529
80.
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT04083976
Protocol IDs
Treatment Sites (2)
Emory University Hospital - Atlanta
Atlanta
University Cancer and Blood Center, LLC - Athens Medical Oncology
Athens
Jamie Hodgson
706-353-2990 x279
81.
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Cancer Type
Bladder Cancer, Unknown Primary
NCI ID
NCT04172675
Protocol IDs
CR108699
NCI-2020-00674
42756493BLC2003
2019-002449-39
82.
A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT04764474
Protocol IDs
2020-306-GLOB1
NCI-2021-03247
83.
A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT04762602
Protocol IDs
2020-306-GLOB2
NCI-2021-01982
84.
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT04133636
Protocol IDs
CR108581
2018-004124-10
68284528MMY2003
NCI-2019-07363
85.
A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants
Cancer Type
Prostate Cancer , Unknown Primary
NCI ID
NCT05022849
Protocol IDs
CR108972
NCI-2021-12359
75229414MPC1001
86.
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
Cancer Type
Breast Cancer
NCI ID
NCT04188548
Protocol IDs
17502
2019-003581-41
J2J-MC-JZLA
NCI-2020-06404
87.
A Study of LY3484356 in Women With Breast Cancer Before Having Surgery
Cancer Type
Breast Cancer, Unknown Primary
NCI ID
NCT04647487
Protocol IDs
17575
NCI-2021-00207
J2J-MC-JZLB
2020-002810-42
88.
A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT03215030
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
89.
A Study of Nivolumab and Ipilimumab in Untreated Participants With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery
Cancer Type
Lung Cancer, Unknown Primary
NCI ID
NCT04026412
Protocol IDs
CA209-73L
NCI-2019-08594
2019-001222-98
90.
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
Cancer Type
Bone Tumor
NCI ID
NCT04100018
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
91.
A Study of NKT2152, a HIF2a Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT05119335
Protocol IDs
NKT2152-101
NCI-2021-13434
92.
A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Cancer Type
Lymphoma
NCI ID
NCT02600897
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
93.
A Study of ONO-7475 in Patients With Acute Leukemias
Cancer Type
Leukemia, Myelodysplastic Syndromes (MDS)
NCI ID
NCT03176277
Protocol IDs
ONO-7475-01
NCI-2017-01115
94.
A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL
Cancer Type
Leukemia, Lymphoma, Non-Hodgkin Lymphoma
NCI ID
NCT03740529
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
95.
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT04736706
Protocol IDs
6482-012
MK-6482-012
NCI-2021-05629
2020-002216-52
96.
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Cancer Type
Lymphoma, Neuroblastoma
NCI ID
NCT02332668
Protocol IDs
3475-051
NCI-2015-00528
2014-002950-38
97.
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)
Cancer Type
Head and Neck Cancer, Unknown Primary
NCI ID
NCT04199104
Protocol IDs
7902-010
MK-7902-010
NCI-2020-00576
2019-003717-34
205240
LEAP-10
98.
A Study of RGX-104 in Patients With Advanced Solid Malignancies and Lymphoma
Cancer Type
Gynecologic Cancers, Lung Cancer, Lymphoma, Neuroendocrine Tumor, Ovarian Cancer, Primary Peritoneal Cancer, Solid Tumor
NCI ID
NCT02922764
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
99.
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Cancer Type
Brain & Spinal Cord Tumor, Colon/Rectal Cancer, Head and Neck Cancer, Lung Cancer, Neuroendocrine Tumor, Solid Tumor, Thyroid Cancer, Unknown Primary
NCI ID
NCT03157128
Protocol IDs
Treatment Sites (1)
Emory University School of Medicine
Atlanta
100.
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
Cancer Type
Head and Neck Cancer, Neuroendocrine Tumor, Thyroid Cancer, Unknown Primary
NCI ID
NCT04211337
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
101.
A Study of SNDX-5613 in R/R Leukemias Including Those With an MLLr/KMT2A Gene Rearrangement or NPM1 Mutation
Cancer Type
Leukemia
NCI ID
NCT04065399
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
102.
A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment
Cancer Type
Lung Cancer
NCI ID
NCT04933695
Protocol IDs
20190288
NCI-2021-12590
2021-002638-18
103.
A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)
Cancer Type
Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Melanoma
NCI ID
NCT03656718
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
104.
A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors
Cancer Type
Breast Cancer
NCI ID
NCT04247126
Protocol IDs
SY-5609-101
NCI-2020-03935
105.
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM)
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT04776018
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
106.
A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Cancer Type
Hematopoietic Malignancies, Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT05050097
Protocol IDs
CR108946
NCI-2021-13605
2020-004502-55
64407564MMY1004
107.
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Cancer Type
Bladder Cancer, Unknown Primary
NCI ID
NCT04658862
Protocol IDs
CR108917
NCI-2021-10015
17000139BLC3001
2020-002620-36
108.
A Study of Tarlatamab (AMG 757) in Participants With Neuroendocrine Prostate Cancer
Cancer Type
Neuroendocrine Tumor, Prostate Cancer , Unknown Primary
NCI ID
NCT04702737
Protocol IDs
20200040
NCI-2021-08862
109.
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT04722146
Protocol IDs
CR108927
NCI-2021-02225
64007957MMY1004
2020-004404-33
110.
A Study of the Drugs Selumetinib versus Carboplatin/Vincristine in Patients with Neurofibromatosis and Low-Grade Glioma
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT03871257
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
111.
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients with Low-Grade Glioma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor
NCI ID
NCT04166409
Protocol IDs
ACNS1833
NCI-2019-07600
ACNS1833
112.
A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies
Cancer Type
Leukemia, Neuroblastoma, Non-Hodgkin Lymphoma
NCI ID
NCT03236857
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
113.
A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)
Cancer Type
Breast Cancer
NCI ID
NCT04740918
Protocol IDs
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
114.
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
Cancer Type
Colon/Rectal Cancer, Lung Cancer, Melanoma
NCI ID
NCT02817633
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
115.
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT04539938
Protocol IDs
SGNTUC-025
NCI-2020-08177
116.
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT03975647
Protocol IDs
Treatment Sites (1)
Georgia Cancer Center at Augusta University
Augusta
117.
A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer
NCI ID
NCT04620330
Protocol IDs
VS-6766-202
NCI-2021-01997
118.
A Study of WVT078 in Patients With Multiple Myeloma (MM)
Cancer Type
Multiple Myeloma
NCI ID
NCT04123418
Protocol IDs
CWVT078A12101
NCI-2021-09189
119.
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors
Cancer Type
Breast Cancer, Lung Cancer
NCI ID
NCT03845166
Protocol IDs
XL092-001
NCI-2019-03738
120.
A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors
Cancer Type
Anal Cancer, Gynecologic Cancers, Head and Neck Cancer, Lung Cancer, Mesothelioma, Penile Cancer, Skin Cancer (Non-Melanoma), Unknown Primary, Uterine Cancer
NCI ID
NCT03517488
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
121.
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
Cancer Type
Head and Neck Cancer
NCI ID
NCT03752398
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
122.
A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion
Cancer Type
Lung Cancer, Pancreatic Cancer
NCI ID
NCT02912949
Protocol IDs
MCLA-128-CL01
NCI-2019-06025
2014-003277-42
123.
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients with Recurrent Glioblastoma with Elevated Mutational Burden
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT04145115
Protocol IDs
A071702
A071702
NCI-2019-07242
124.
A Study to Assess Adjuvant Immunotherapy With Relatlimab and Nivolumab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma
Cancer Type
Melanoma, Unknown Primary
NCI ID
NCT05002569
Protocol IDs
CA224-098
NCI-2022-02119
2021-001641-13
125.
A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT03287908
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
126.
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
Cancer Type
Lung Cancer, Solid Tumor, Unknown Primary
NCI ID
NCT04931654
Protocol IDs
D9570C00001
NCI-2022-01956
152970
2021-000036-57
127.
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
Cancer Type
Solid Tumor, Unknown Primary
NCI ID
NCT04192344
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
128.
A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCI ID
NCT04546399
Protocol IDs
Treatment Sites (1)
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
129.
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients with High Risk Rhabdomyosarcoma
Cancer Type
Sarcoma, Unknown Primary
NCI ID
NCT04994132
Protocol IDs
ARST2031
ARST2031
NCI-2021-06711
130.
A Study to Compare Standard Chemotherapy to Therapy with CPX-351 and/or Gilteritinib for Patients with Newly Diagnosed AML with or without FLT3 Mutations
Cancer Type
Leukemia
NCI ID
NCT04293562
Protocol IDs
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
131.
A Study to Compare T-Guard vs Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-vs-Host Disease (BMT CTN 2002)
Cancer Type
Unknown Primary
NCI ID
NCT04934670
Protocol IDs
BMT CTN 2002
NCI-2021-14060
2021-000343-53
5U24HL138660-02
XEN-TG-005
132.
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases
Cancer Type
Melanoma
NCI ID
NCT04511013
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
133.
A Study to Compare Treatment with the Drug Selumetinib Alone versus Selumetinib and Vinblastine in Patients with Recurrent or Progressive Low-Grade Glioma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary
NCI ID
NCT04576117
Protocol IDs
ACNS1931
ACNS1931
NCI-2020-07549
134.
A Study to Compare Treatments for a Type of Kidney Cancer called TFE/Translocation Renal Cell Carcinoma (tRCC)
Cancer Type
Kidney Cancer, Unknown Primary
NCI ID
NCT03595124
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
135.
A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
Cancer Type
Ovarian Cancer
NCI ID
NCT04251052
Protocol IDs
Treatment Sites (2)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
Summit Cancer Care at the Nancy N. Lewis and J.C. Lewis Cancer & Research Pavilion
Savannah
136.
A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma
Cancer Type
Multiple Myeloma
NCI ID
NCT02773030
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
137.
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Cancer Type
Multiple Myeloma, Plasma cell neoplasm
NCI ID
NCT03989414
Protocol IDs
CC-92480-MM-002
NCI-2019-04130
2018-004767-31
U1111-1233-5619
138.
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
Cancer Type
Unknown Primary, Uterine Cancer
NCI ID
NCT03981796
Protocol IDs
213361
4010-03-001
NCI-2019-04891
GOG-3031
ENGOT-EN6
139.
A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
Cancer Type
Breast Cancer, Esophogeal Cancer, Head and Neck Cancer, Stomach/ Gastric Cancer
NCI ID
NCT04225117
Protocol IDs
Treatment Sites (4)
Piedmont Cancer Institute - Atlanta
Atlanta
Katie Adams
678-298-3238
Piedmont Cancer Institute - Fayetteville
Fayetteville
678-298-3238
Piedmont Cancer Institute - Newnan
Newnan
Katie Adams
678-298-3238
Piedmont Cancer Institute - Stockbridge
Stockbridge
Katie Adams
678-298-3238
140.
A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases
Cancer Type
Sarcoma
NCI ID
NCT04554914
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
141.
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Cancer Type
Hematopoietic Malignancies, Unknown Primary
NCI ID
NCT03011372
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
142.
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
Cancer Type
Bile Duct Cancer
NCI ID
NCT03656536
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
143.
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRa)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Cancer Type
Lung Cancer, Solid Tumor
NCI ID
NCT04300556
Protocol IDs
MORAb-202-G000-201
NCI-2020-06147
2019-003600-12
144.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Cancer Type
Multiple Myeloma
NCI ID
NCT04045028
Protocol IDs
Treatment Sites (1)
Emory Clinic
Atlanta
145.
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors
Cancer Type
Bile Duct Cancer, Gynecologic Cancers, Ovarian Cancer, Prostate Cancer
NCI ID
NCT04972981
Protocol IDs
ADCT-901-101
NCI-2021-10797
2021-002292-19
146.
A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD
Cancer Type
Unknown Primary
NCI ID
NCT03763318
Protocol IDs
Treatment Sites (1)
Emory University Hospital - Atlanta
Atlanta
147.
A Study to Examine How Often (Every 5 Years or 10 Years) a Colonoscopy Should be Done in Participants Who Had One or Two Small Growths of Tissue Removed from Their Colon
Cancer Type
Colon/Rectal Cancer
NCI ID
NCT05080673
Protocol IDs
NRG-CC005
NRG-CC005
NRG-CC005
NCI-2020-00733
148.
A Study to Investigate Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed B-Lymphoblastic Leukemia
Cancer Type
Leukemia
NCI ID
NCT03914625
Protocol IDs
Treatment Sites (4)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913
149.
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer
Cancer Type
Breast Cancer
NCI ID
NCT04946864
Protocol IDs
APG2575XU103
NCI-2021-11630
150.
A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for Delta-Like Ligand 3 (DLL3).
Cancer Type
Lung Cancer
NCI ID
NCT04429087
Protocol IDs
1438-0001
NCI-2021-01392
2019-000729-31
151.
A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary
NCI ID
NCT03776071
Protocol IDs
DB102-01
NCI-2020-13730
152.
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
Cancer Type
Brain & Spinal Cord Tumor
NCI ID
NCT03970447
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
153.
A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors
Cancer Type
Bile Duct Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Stomach/ Gastric Cancer
NCI ID
NCT04396821
Protocol IDs
TST001-1001
NCI-2020-05881
154.
Abatacept Extended Dosing Compared to Abatacept Short-Term Dosing for the Prevention of Graft versus Host Disease, ABA3 Study
Cancer Type
Hematopoietic Malignancies
NCI ID
NCT04380740
Protocol IDs
20-227
NCI-2022-03010
155.
Abemaciclib and Letrozole to Treat Endometrial Cancer
Cancer Type
Unknown Primary, Uterine Cancer
NCI ID
NCT04393285
Protocol IDs
Treatment Sites (1)
Nancy N. and J.C. Lewis Cancer Research Pavilion at St. Joseph Candler
Savannah
Alaina Underberg
912-819-5778
156.
Abemaciclib and Radiation Therapy in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Recurrent or Refractory Solid Tumors, or Malignant Brain Tumors
Cancer Type
Brain & Spinal Cord Tumor, Neuroblastoma, Sarcoma
NCI ID
NCT02644460
Protocol IDs
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
157.
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCI ID
NCT04883437
Protocol IDs
WINSHIP5186-20
NCI-2021-00894
STUDY00002247
158.
Accelerated or Standard BEP Chemotherapy in Treating Patients with Intermediate or Poor-Risk Metastatic Germ Cell Tumors
Cancer Type
Germ Cell Tumor, Testicular Cancer
NCI ID
NCT02582697
Protocol IDs
Treatment Sites (2)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
159.
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors
Cancer Type
Germ Cell Tumor, Testicular Cancer
NCI ID
NCT03067181
Protocol IDs
Treatment Sites (2)
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
160.
Actuate 1901: 9-ING-41 in Myelofibrosis
Cancer Type
Leukemia
NCI ID
NCT04218071
Protocol IDs
1901
NCI-2020-01824
161.
Additional Support Program via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
Cancer Type
Breast Cancer
NCI ID
NCT04379570
Protocol IDs
A191901
A191901
A191901
NCI-2020-02479
162.
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
Cancer Type
Hematopoietic Malignancies, Solid Tumor
NCI ID
NCT03391778
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
163.
Afatinib Dimaleate in Treating Patients with Advanced Refractory Urothelial Cancer
Cancer Type
Bladder Cancer, Unknown Primary, Urethral Cancer
NCI ID
NCT02122172
Protocol IDs
IRB13-0540
NCI-2014-00859
13-0540
164.
AFP?³³²T in Advanced HCC
Cancer Type
Liver Cancer / Hepatoblastoma
NCI ID
NCT03132792
Protocol IDs
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
165.
Alisertib Alone or in Combination with Chemotherapy and Radiation Therapy in Treating Younger Patients with Recurrent, Progressive, or Newly Diagno